- Home
- CDTG vs AEON Comparison
CDTG vs AEON Comparison
Compare CDTG & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- AEON
- Stock Information
- Founded
- CDTG 2012
- AEON N/A
- Country
- CDTG China
- AEON United States
- Employees
- CDTG N/A
- AEON N/A
- Industry
- CDTG
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- AEON Health Care
- Exchange
- CDTG NYSE
- AEON Nasdaq
- Market Cap
- CDTG 34.6M
- AEON 36.4M
- IPO Year
- CDTG 2024
- AEON N/A
- Fundamental
- Price
- CDTG $3.77
- AEON $0.64
- Analyst Decision
- CDTG
- AEON Strong Buy
- Analyst Count
- CDTG 0
- AEON 1
- Target Price
- CDTG N/A
- AEON $5.00
- AVG Volume (30 Days)
- CDTG 200.4K
- AEON 285.0K
- Earning Date
- CDTG 12-24-2024
- AEON 11-13-2024
- Dividend Yield
- CDTG N/A
- AEON N/A
- EPS Growth
- CDTG 28.29
- AEON N/A
- EPS
- CDTG 0.81
- AEON 0.34
- Revenue
- CDTG $34,209,919.00
- AEON N/A
- Revenue This Year
- CDTG N/A
- AEON N/A
- Revenue Next Year
- CDTG N/A
- AEON N/A
- P/E Ratio
- CDTG $4.70
- AEON $1.84
- Revenue Growth
- CDTG 18.58
- AEON N/A
- 52 Week Low
- CDTG $2.12
- AEON $0.52
- 52 Week High
- CDTG $4.60
- AEON $17.17
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- AEON 46.56
- Support Level
- CDTG N/A
- AEON $0.61
- Resistance Level
- CDTG N/A
- AEON $0.85
- Average True Range (ATR)
- CDTG 0.00
- AEON 0.12
- MACD
- CDTG 0.00
- AEON 0.01
- Stochastic Oscillator
- CDTG 0.00
- AEON 28.50
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.